Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory and autoimmune disease. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.

3 drug assets in development

Invion has three drug assets in development across four programs. Two phase 2 clinical trials reported data in 2015 with a further phase 2 trial due to report data in 2016. Hear CMO Dr Mitchell Glass discuss the results of Invion's successful P2 clinical trial in smoking cessation.